ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO ), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the appointments of Scott Garland as Chairman of the Board of Directors (the "Board") and Michael Listgarten as